國藥集團:中國生物新冠滅活疫苗安全有效
國藥集團官方微信公眾號發文稱,目前國藥集團中國生物的新冠病毒滅活疫苗已在中國、阿聯酋、巴林獲批註冊上市,在中國、阿聯酋、巴林、埃及獲批緊急使用。
截至2021年1月4日,國內緊急使用已接種國藥集團中國生物新冠滅活疫苗逾400萬劑次,中國生物已合計發運疫苗用於國內緊急使用逾1,000萬劑。目前國藥集團新冠疫苗在大規模緊急使用中,未接到嚴重不良反應報告。國內緊急使用接種疫苗後已赴海外7.2萬人,共去往156個國家和地區,特別是其中赴疫情高風險國家的外交人員、駐國際組織代表、中資企業員工等,雖然與當地感染者有密切接觸,但均未感染發病。新冠滅活疫苗的安全性、有效性得到進一步驗證。(ta/w) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.